Male breast cancer accounts for 0.5-1% of all breast cancers. Risk factors are age, heredity, testicular disease, hyperestrogenism, Klinefelter’s syndrome. In men there is a BRCA1 gene mutation at a rate of 0-4% and a BRCA2 gene mutation at a rate of 4-6%. Mutations in the CHEK2 and PALB2 genes are also possible. That is why genetic counseling by an oncologist-geneticist is necessary for men. Cancer in men is usually advanced at diagnosis and histologically it is usually a squamous cell carcinoma. Generally, male breast cancer is hormone receptor positive. In a study by the International Male Breast Cancer Program conducted in 1. 483 men with breast cancer showed that 99% were estrogen receptor positive, 82% progesterone positive, 97% androgen positive, 9% her2 positive and 1% triple negative. Prognostic factors are the same as for women. Usually 85% of men undergo a mastectomy. Post-operative oncological treatment of the patient is no different from female treatment. The treatment protocols are almost the same as for women. Tamoxifen is administered as hormone therapy and not aromatase inhibitors. The treatment protocols are almost the same as for women. Tamoxifen is administered as hormone therapy and not aromatase inhibitors. The treatment protocols are almost the same as for women. Tamoxifen is administered as hormone therapy and not aromatase inhibitors.